Vaping and oral snuff products containing synthetic nicotine analogues have been found in the US marketplace this year. These products are promoted as exempt from the US Food and Drug Administration (FDA) premarket tobacco product application (PMTA) process and avoid federal and state regulations.
This report explains what nicotine analogues are and what their current US federal legal status is, looks at criticism for the FDA’s lack of regulations on them, and predicts the future of these compounds in the country.
Kristina holds a Masters Degree in International Law from Moscow State Linguistic University, Russia. In 2020 she completed a six-month exchange programme at the University of Malaga. She has worked as a legal secretary at the Ninth Arbitration Court of Appeal, Russia; and as a legal assistant in a law firm in Moscow.
Our Key Benefits
The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
"*" indicates required fields
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis.
LATEST ALERTS
